Welcome to our dedicated page for Cogent Biosciences news (Ticker: COGT), a resource for investors and traders seeking the latest updates and insights on Cogent Biosciences stock.
Cogent Biosciences, Inc. (NASDAQ: COGT) is a pioneering biotechnology company focused on developing precision therapies for genetically defined diseases. Headquartered in Waltham, MA, and Boulder, CO, Cogent's mission is to design rational, targeted therapies that treat the underlying causes of disease, thereby improving the lives of patients. The company's lead program, bezuclastinib, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation and other mutations in KIT exon 17. This mutation is a key driver of Systemic Mastocytosis (SM) and Advanced Gastrointestinal Stromal Tumors (GIST), both serious diseases dependent on oncogenic KIT signaling.
Bezuclastinib is undergoing rigorous clinical trials, with the PEAK, SUMMIT, and APEX trials all targeted toward specific genetic mutations associated with these diseases. The company has made significant strides in 2024, including the initiation of a new Phase 2 clinical trial of bezuclastinib in later line GIST patients in collaboration with the Sarcoma Alliance for Research through Collaboration (SARC), The Life Raft Group, and Dana-Farber Cancer Institute.
In addition to bezuclastinib, the Cogent Research Team is developing a portfolio of novel targeted therapies focused on mutations in FGFR2, ErbB2, and PI3Kα. These programs aim to create therapies with potential best-in-class properties, targeting rare and genetically driven diseases.
The company recently secured $225 million in a private investment led by prominent investors, ensuring a robust financial position that supports its ambitious research and development goals. Cogent's financial stability is further reinforced by a strong cash runway projected to extend into 2027, allowing the company to complete its ongoing and planned clinical trials.
Latest News:
- February 26, 2024: Cogent announces a successful $225 million funding round, enhancing its financial stability.
- February 22, 2024: Positive Part 1b data from the ongoing SUMMIT trial evaluating bezuclastinib in NonAdvSM patients.
- February 14, 2024: New Phase 2 clinical trial of bezuclastinib in later line GIST patients announced in collaboration with SARC.
- January 9, 2024: Key milestones for 2024 highlighted at J.P. Morgan’s 42nd Annual Healthcare Conference.
For more detailed and updated information, visit Cogent Biosciences' official website and follow them on social media platforms like X (formerly known as Twitter) and LinkedIn.
Cogent Biosciences (COGT) announced significant advancements in its pipeline during the AACR 2023 Annual Meeting. The company presented updated preclinical data on a novel EGFR-sparing, brain-penetrant ErbB2 inhibitor targeting key mutations, showcasing improved potency and selectivity. Additionally, the company initiated Part 2 of its APEX trial for bezuclastinib, dosing 150 mg daily in Advanced Systemic Mastocytosis (AdvSM). This second phase aims to enroll 65 patients and potentially support regulatory submissions upon success. The enhanced formulation of bezuclastinib is expected to yield better clinical exposure compared to the prior dosage. Upcoming clinical data updates from both APEX and other trials are anticipated in late 2023.
Cogent Biosciences, Inc. (Nasdaq: COGT) has announced its participation in two upcoming virtual investor conferences. The first is the 22nd Annual Needham Healthcare Conference scheduled for April 19, 2023, at 2:15 p.m. ET. The second event is the Stifel 2023 Targeted Oncology Days on April 25, 2023, at 12:30 p.m. ET. Investors can access live webcasts of these conferences on Cogent's Investors & Media page, with replays available within two hours after each event, lasting for 30 days. Cogent, based in Waltham, MA, and Boulder, CO, focuses on precision therapies for genetically defined diseases, with bezuclastinib being its advanced clinical program targeting specific mutations linked to serious conditions like systemic mastocytosis and gastrointestinal stromal tumors.
Cogent Biosciences (Nasdaq: COGT) announced significant developments in Q4 2022, including the initiation of the Phase 3 PEAK trial for gastrointestinal stromal tumors (GIST) and positive clinical data for bezuclastinib in systemic mastocytosis. Cash reserves stood at $259.3 million, sufficient to fund operations until 2025. The company aims to advance multiple clinical programs in 2023, with key data expected from the Phase 2 SUMMIT trial for NonAdvSM and updated results from Phase 3 PEAK. However, the net loss grew to $39.6 million in Q4 2022, and R&D expenses increased significantly to $36.7 million.
Cogent Biosciences (Nasdaq: COGT) announced its participation in two upcoming investor conferences in February 2023. Andrew Robbins, President and CEO, will present at the Guggenheim Healthcare Talks Idea Forum Oncology Day on February 8 at 10:10 a.m. ET, and the SVB Securities Global Biopharma Conference on February 14 at 9:20 a.m. ET. Interested investors can access live webcasts of these events on the Investors & Media page of Cogent's website, with replays available for 30 days post-event. Cogent focuses on precision therapies for genetically defined diseases, including bezuclastinib for systemic mastocytosis and advanced gastrointestinal stromal tumors.
Cogent Biosciences (COGT) is advancing its portfolio in 2023 with key milestones. The company is set to announce mid-year results from its Phase 2 APEX trial in Advanced Systemic Mastocytosis (AdvSM) and initial data from the Phase 2 SUMMIT trial in Non-Advanced SM later this year. Also, bezuclastinib's clinical progress includes updates from the Phase 3 PEAK trial for Gastrointestinal Stromal Tumors (GIST), expanding to over 100 global sites. Cogent aims to enhance its pipeline with new targeted cancer therapies, anticipating a total of five distinct programs by the end of 2023.
Cogent Biosciences (COGT) announced that CEO Andrew Robbins will present at the 41st Annual J.P. Morgan Healthcare Conference on January 12, 2023, at 7:30 a.m. PT. A live webcast will be accessible on the company’s website, with a replay available post-event for 30 days. Cogent focuses on precision therapies for genetically defined diseases, notably developing bezuclastinib, a selective tyrosine kinase inhibitor targeting the KIT D816V mutation. The company aims to address serious diseases like systemic mastocytosis and advanced gastrointestinal stromal tumors.
Cogent Biosciences (COGT) reported positive updated data from its ongoing Phase 2 APEX clinical trial for the TKI D816V inhibitor bezuclastinib in patients with advanced systemic mastocytosis (AdvSM). Key findings include an 89% overall response rate (ORR) in TKI-therapy naïve patients and a 73% ORR in all evaluable patients after 27 weeks of median follow-up. Safety results show no cognitive side effects or intracranial bleeding events. Cogent will continue patient enrollment in APEX and other trials for broader indications, with updates planned for 2023.
FAQ
What is the current stock price of Cogent Biosciences (COGT)?
What is the market cap of Cogent Biosciences (COGT)?
What does Cogent Biosciences, Inc. specialize in?
What is the main clinical program of Cogent Biosciences?
Where is Cogent Biosciences headquartered?
What recent achievements has Cogent Biosciences accomplished?
What are the financial prospects of Cogent Biosciences?
What other programs is Cogent developing besides bezuclastinib?
How can I stay updated with Cogent Biosciences' latest news?
What are Cogent Biosciences' key clinical trials?
Who are Cogent Biosciences' key collaborators?
How does bezuclastinib work?
